Want to see CTEV full AI Analyst Report?
CTEV Stock Chart & Stats
$47.12
--
Market closed
$47.12
--
Day’s Range― - ―
52-Week Range$11.50 - $74.07
Previous CloseN/A
VolumeN/A
Average Volume (3M)189.96K
Market Cap
$501.55M
Enterprise Value$5.09B
Total Cash (Recent Filing)$21.33M
Total Debt (Recent Filing)$4.61B
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Jul 30, 2026EPS Estimate
-4.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.33
Shares Outstanding17,047,789
10 Day Avg. Volume100,946
30 Day Avg. Volume189,963
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-4.04
Price to Sales (P/S)0.73
P/FCF Ratio-57.23
Enterprise Value/Market Cap10.16
Enterprise Value/Revenue5.21
Enterprise Value/Gross Profit8.52
Enterprise Value/Ebitda9.85
Forecast
1Y Price Target
$39.80Price Target Upside-15.53% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-16.02
Revenue Forecast (FY)$989.60M
Bulls Say, Bears Say
Bulls Say
High Adjusted EBITDA MarginsSustained very high adjusted EBITDA margins indicate a structurally profitable core business and strong operating leverage. High margins provide durable internal funding for investments and cushioning against revenue variability, supporting reinvestment and margin resilience as ACV ramps.
Robust ACV Bookings And PipelineLarge, growing ACV pipeline and meaningful uplift in seven‑figure deals provide multi-quarter revenue visibility and recurring revenue expansion. Strong cross‑sell (73%) and ~4.8x pipeline coverage support predictable conversion into revenue over 6–12 months, underpinning sustainable top‑line growth.
AI-driven Operational EfficienciesAutomation and AI materially raise capacity without proportional headcount growth, lowering incremental cost to serve and improving unit economics. These durable productivity gains support scalable growth, protect margins as services scale, and reduce long‑term operating expense intensity.
Bears Say
Very High Leverage And Negative EquityA heavily indebted balance sheet with negative equity constrains financial flexibility and heightens refinancing and covenant risk. Large debt relative to assets increases sensitivity to cash‑flow swings and limits ability to fund investments or absorb shocks without costly external financing or dilution.
Inconsistent Free Cash Flow And Persistent Net LossesWhile operating cash flow helps near‑term liquidity, inability to consistently generate positive free cash flow plus recurring net losses reduces capacity to pay down debt or self‑fund growth. Reliance on non‑operating adjustments and one‑offs creates earnings volatility that may limit durable deleveraging.
DOJ Civil Antitrust InquiryAn active civil DOJ inquiry is a sustained legal and regulatory overhang that can divert management focus, increase compliance costs, and create contracting uncertainty—notably as the company pursues public‑sector and large health‑system deals—potentially delaying expansion and revenue realization.
Claritev News
CTEV FAQ
What was Claritev Corporation’s price range in the past 12 months?
Claritev Corporation lowest stock price was $11.50 and its highest was $74.07 in the past 12 months.
What is Claritev Corporation’s market cap?
Claritev Corporation’s market cap is $501.55M.
When is Claritev Corporation’s upcoming earnings report date?
Claritev Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 27 days.
How were Claritev Corporation’s earnings last quarter?
Claritev Corporation released its earnings results on May 07, 2026. The company reported -$4.41 earnings per share for the quarter, missing the consensus estimate of -$4.086 by -$0.324.
Is Claritev Corporation overvalued?
According to Wall Street analysts Claritev Corporation’s price is currently Overvalued.
Does Claritev Corporation pay dividends?
Claritev Corporation does not currently pay dividends.
What is Claritev Corporation’s EPS estimate?
Claritev Corporation’s EPS estimate is -4.12.
How many shares outstanding does Claritev Corporation have?
Claritev Corporation has 17,047,789 shares outstanding.
What happened to Claritev Corporation’s price movement after its last earnings report?
Claritev Corporation reported an EPS of -$4.41 in its last earnings report, missing expectations of -$4.086. Following the earnings report the stock price went down -8.538%.
Which hedge fund is a major shareholder of Claritev Corporation?
Currently, no hedge funds are holding shares in CTEV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Claritev Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.80 (-15.53% Downside)
$39.80 (-15.53% Downside)
Blogger Sentiment
Neutral
CTEV Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 61.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $493.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.72%
12-Months-Change
Fundamentals
Return on Equity
205.84%
Trailing 12-Months
Asset Growth
-4.82%
Trailing 12-Months
Company Description
Claritev Corporation
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.
CTEV Company Deck
CTEV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial trajectory: revenue and adjusted EBITDA outperformed expectations, ACV bookings and pipeline showed strong momentum (+70% pipeline growth, $44.1M ACV in Q1), and AI-driven efficiencies are producing measurable productivity gains. Management is investing to expand services and enter new verticals (public sector, large health systems) while maintaining full-year EBITDA guidance and raising the bottom end of revenue guidance. Near-term headwinds include modest PSAV volume declines, the expected cash-consumption pattern in Q1/Q3 due to working capital and interest normalization, and lower-margin services during ramp; however, these were presented as deliberate, invest-to-scale initiatives with visibility into ACV conversion and revenue ramping in 6–12 months.View all CTEV earnings summariesCTEV Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$39.80
▼(-15.53% Downside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
HealthStream
―
Evolent Health
―
Health Catalyst
―
Clinigence Holdings
―
Definitive Healthcare Corp
―
Ownership Overview
16.78% Insiders
29.76% Mutual Funds
27.47% Other Institutional Investors
19.84% Public Companies and
Individual Investors










